Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation

摘要: Respiratory syncytial virus (RSV), one of the most common causes respiratory infections in immunocompetent individuals, can cause significant pulmonary morbidity and mortality hematopoietic stem cell (HSCT) less often solid-organ transplant recipients. Early diagnosis medical intervention prior to progression from upper lower tract viral involvement is essential positively affect clinical course. The greatest risk disease during early posttransplant period for HSCT recipients, with lymphopenia being an important factor. Polymerase chain reaction has become preferred method rapidly diagnosing infection this population because higher sensitivity compared traditional culture direct antigen methods. Despite lack prospective randomized trials, retrospective pooled analyses have suggested that systemically delivered ribavirin (either aerosolized, oral, or IV; without immunomodulator therapy) decrease disease. Additionally, there are a number trials currently process evaluate several new agents target RSV high-risk patient population.